A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Trial Profile

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs DAS 181 (Primary)
  • Indications Parainfluenza virus infections
  • Focus Therapeutic Use
  • Sponsors Ansun Biopharma
  • Most Recent Events

    • 18 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 02 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
    • 02 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top